A spin probe study of the effects of chlorpromazine and its derivatives on lipid-protein interactions in synaptosomal membranes.
The electron spin resonance spectra of 16-doxyl stearic acid (16-SA) incorporated into synaptosomes mostly showed a fluid lipid component and a minor motionally-restricted component (MRC) of the molar fraction of 10-20%, measured at 0 degree C. At 10 mmol/l concentration, thioridazine (TRZ), chlorpromazine (CPZ), chlorprothixene (CPT), perphenazine (PFZ) and levopromazine (LPZ) raised the MRC molar fraction in the synaptosomes to 100, 92, 65, 41 and 39%, respectively (as detected by the spin probe at 0 degrees C). At 4% concentration, TRZ, CPZ, CPT, PFZ, and LPZ the respective MRC percentages were 100, 75, 41, 24 and 17%. In synaptosomal membranes, AMRC splitting values of MRC, induced by TRZ and CPZ, were similar to those of the probe in human serum albumin. MRC induced by CPZ and TRZ was constant (+/- 15%) within the temperature range from 0 to 30 degrees C. At drug/lipid ratios > or = 2 : 1, TRZ and CPZ formed rigid complexes with total lipids isolated from the rat brain. The complexes melted upon increasing the temperature of the samples over 10-20 degrees C. The drugs decreased the lipid concentrations in synaptosomes in the order of potency TRZ > CPZ > CPT > PFZ > or = LPZ; this was similar to their effect on MRC increase. The drugs tested increased the membrane dynamics/disordering, and their potency fairly correlated with their MRC increasing effects. It is supposed that the drug-induced 16-SA probe MRC increase in synaptosomes was a result of mainly decreased lipid/protein ratio in the synaptosomal membranes, which in turn probably is connected with perturbation of lipid-protein interactions and/or membrane proteins. The perturbation of lipid-protein interactions and/or membrane proteins may be connected with the drug perturbation effect on the bulk lipid membrane part.
Ondrias
K
K
Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava.
Biskupic
S
S
Stasko
A
A
Pogády
J
J
D000818:Animals; D002746:Chlorpromazine / Q000031:analogs & derivatives / Q000494:pharmacology*; D003497:Cyclic N-Oxides; D004578:Electron Spin Resonance Spectroscopy; D066298:In Vitro Techniques; D008560:Membrane Fluidity / Q000187:drug effects; D008563:Membrane Lipids / Q000378:metabolism; D008565:Membrane Proteins / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D013113:Spin Labels; D013574:Synaptosomes / Q000187:drug effects* / Q000378:metabolism
D003497:Cyclic N-Oxides; D008563:Membrane Lipids; D008565:Membrane Proteins; D013113:Spin Labels; C032363:16-nitroxystearic acid; D002746:Chlorpromazine